Developer docs
API playgroundTry for free, no card

Search company profiles

MSD Romania

Full company profile

uuid004xhae

Namestring
MSD Romania
Legal namestring
Merck Sharp & Dohme Romania SRL
Websiteurl
msd.ro
Company typeenum
Private
Founded yearstring
-
Descriptiontext

MSD Romania operates as Merck Sharp & Dohme Romania SRL, a wholly-owned subsidiary of Merck & Co., Inc. (NYSE: MRK) and the local affiliate of the global pharmaceutical company known as MSD outside North America. The Romanian entity commercializes the parent company's innovative prescription medicines across four primary therapeutic areas: oncology, vaccines, infectious diseases, and cardiovascular/metabolic diseases. It serves the Romanian market and, following a regional restructuring into the MEDEBA cluster, extends coverage to the Republic of Moldova. The subsidiary employs approximately 136 staff focused on medical affairs, market access, regulatory, and commercial field operations supporting physicians, hospitals, and the national health insurance system.

The company's core product portfolio mirrors the parent company's global launches in oncology and vaccines, with established positions in immuno-oncology (Keytruda-class therapies inherited from group development), HPV and other vaccines, HIV antiretrovirals (expanded via the 2021 Gilead partnership), and chronic disease treatments. Its business model is a classic multinational pharma go-to-market: it sells reimbursed prescription medicines primarily through the National Health Insurance House (CNAS/NHIH) framework, with secondary channels through hospital tenders, retail pharmacies, and physician-detailing field forces. Revenue mechanics depend on obtaining and maintaining reimbursement listings, winning hospital tenders, and driving physician adoption — a model exposed to public-procurement cycles and reference-pricing pressure. No local manufacturing is indicated; products are supplied through the group's regional and global supply chain.

Beyond commercial operations, MSD Romania has built a public-health and CSR footprint, including the MSD for Mothers partnership with World Vision Romania (2016) targeting maternal mortality, a $50,000 cancer health-literacy research grant with Babeș-Bolyai University (2023), and participation in the AMR Industry Alliance (2016) and AMR Action Fund (2020). In 2023 the company achieved Best Place to Work certification, indicating investment in employer brand in a competitive CEE pharma talent market. Following the May 2026 leadership transition — Conor Dempsey replacing Marcelo Pascual Morales as Managing Director — the affiliate is positioned for continued emphasis on oncology, vaccines, and cardio-metabolic franchises within Romania and Moldova.

Short descriptiontext

MSD Romania (Merck Sharp & Dohme Romania SRL) is the Romanian and Moldovan affiliate of Merck & Co., commercializing innovative prescription medicines in oncology, vaccines, infectious diseases, and cardiovascular/metabolic diseases through NHIH reimbursement, hospital channels, and physician field forces.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersBucurești, Romania
HQ citystring
București
HQ countrystring
Romania
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
prescription pharmaceuticals, vaccine development, oncology therapies, infectious disease treatments, animal health products
Industry2 codes
PRIMARYHLAIAEAN
Vaccine Procurement, Tendering & Immunization Supply Programs
SECONDARYAFAEANAK
Veterinary Pharmacy, Vaccine & Biologics Services
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Biopharmaceuticals
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Prescription Medicines
TypeOthers
Description

MSD generates revenue through prescription pharmaceutical products including oncology treatments, cardiovascular medications, diabetes treatments, and other therapeutic areas. Revenue is generated through healthcare provider prescriptions and hospital procurement.

msd.ro
2Vaccines
TypeOthers
Description

Revenue from vaccine products including HPV vaccine, pediatric vaccines (rotavirus, measles-mumps-rubella), and adult vaccines. Distributed approximately 203 million doses globally in 2022.

msd.ro
3Hospital Acute Care Products
TypeOthers
Description

Products for hospital settings including antibiotics and antifungics for inpatient care, contributing to the Hospital Acute Care division.

msd.ro
4Animal Health Products
TypeOthers
Description

MSD Animal Health division provides veterinary products and vaccines, operating as a separate business unit with global presence.

msd.ro
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Marketing or Sales, Supply Chain, Operations
Pricing details1 tier
1Standard pharmaceutical pricing through prescription and hospital procurement
ModelOtherBilling cadenceMulti-year contract
Notes

Pricing for prescription medicines and vaccines is determined through government healthcare procurement, insurance reimbursement negotiations, and regulated pricing frameworks typical of the pharmaceutical industry.

msd.ro
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1MSD for Mothers
Description

A 10-year, $500 million initiative that applies MSD's scientific expertise and business resources to reduce maternal mortality globally. In Romania, MSD for Mothers partnered with World Vision Romania in 2016.

msd.ro
+2 more records
Core offering1 text field

MSD Romania is the Romanian subsidiary of Merck & Co., Inc., operating as a biopharmaceutical company that develops, manufactures, and distributes prescription medicines, vaccines, and animal health products across therapeutic areas including oncology, vaccines, infectious diseases (HIV, hepatitis C, antibiotics, antifungals), cardiovascular and metabolic diseases (including type 2 diabetes), and hospital acute care. The company sells primarily to hospitals, healthcare providers, government health programs, and pharmacies, with a separate MSD Animal Health division serving veterinarians and livestock producers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 400,000+ oncology patients treated in the last 5 years
+4 more records
Product overview1 text field

MSD Romania operates as the Romanian subsidiary of Merck Sharp & Dohme (MSD), a global biopharmaceutical company known as Merck & Co. in the US and Canada. The company offers a comprehensive portfolio of prescription medicines and vaccines across multiple therapeutic areas including oncology (with treatments for 30+ cancer types), vaccines (protecting against 20+ diseases with 203M doses distributed globally in 2022), infectious diseases (HIV with 35 years of research, Ebola, antibiotics since 1942), cardiovascular and metabolic diseases (including diabetes), and hospital care products. MSD also operates an Animal Health division. The company's research and development process encompasses drug discovery, pre-clinical development, clinical development, and real-world evidence generation through its CORE center. With over 130 years of pharmaceutical innovation, MSD Romania focuses on bringing innovative medicines to the Romanian market through its network of operations in Romania and the Republic of Moldova.

Product and service1 record
1Oncology Therapies
Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-03-27
Description

Departamentul de Sănătate Publică al Universității Babeș-Bolyai and MSD România launched a health policy research project analyzing how improving cancer literacy can reduce inequities in cancer treatment. The project, funded with $50,000 through MSD's Global Cancer Health Policy Grants Program, will develop policy recommendations to improve access to information and medical services for oncology patients. Implemented over 12 months using evidence-based and personalized approaches in the bio-psycho-social model framework.

2Onco-alliance (Slovakia)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-11-01
Description

Strategic oncology alliance supporting implementation of European-funded projects worth over 8 million euros for oncology infrastructure and digitization. Projects focused on colon cancer, breast cancer, and lung cancer improvement initiatives.

msd.ro
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2021-01-01
Description

MSD entered into an agreement with Gilead to collaborate within the global HIV community in the fight against HIV, combining capabilities to address this ongoing public health challenge.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2020-01-01
Description

MSD, together with over 20 leading biopharmaceutical companies, launched the AMR Action Fund to make 2-4 new antibiotics available to patients by the end of the decade. This initiative addresses the critical need for new antimicrobial treatments in the face of growing resistance.

5World Vision România
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2016-01-01
Description

MSD Romania and World Vision Romania Foundation launched a comprehensive program to reduce maternal mortality in Romania as part of the global MSD for Mothers initiative. The program develops an integrated and innovative model of family planning, reproductive health, and pregnant women assistance services in disadvantaged areas of the country. The global MSD for Mothers initiative is a 10-year, $500 million commitment to reducing maternal mortality globally.

msd.ro
6AMR Industry Alliance
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2016-01-01
Description

MSD joined the AMR Industry Alliance, a network of over 100 pharmaceutical industry partners working to provide sustainable solutions to help reduce antimicrobial resistance. The alliance represents one of the largest private sector coalitions addressing AMR globally.

msd.ro
Strategic tierMinorTypeStrategic or Co-development Partner
Description

MSD participates as an industry representative in the One Health Global Leaders Group on Antimicrobial Resistance, advocating for a One Health approach to ensure antibiotics remain an important tool for improving and maintaining human and animal health.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Romanian subsidiary of Sanofi S.A., with strong overlap in vaccines, diabetes, and rare diseases. Comparable to MSD Romania in pediatric and adult vaccine portfolios and in diabetes/cardio-metabolic therapeutic areas.

TypeDirect peer
Description

Romanian subsidiary of Roche Group with a strong oncology and diagnostics overlap. Directly comparable to MSD Romania in oncology positioning, hospital channel focus, and participation in national cancer control planning.

TypeDirect peer
Description

Romanian subsidiary of Novartis AG covering oncology, cardiovascular, and immunology portfolios. Comparable to MSD Romania as a top-tier multinational pharma subsidiary competing for hospital formularies and reimbursement in Romania.

TypeDirect peer
Description

Romanian pharmaceutical operations of Johnson & Johnson covering oncology, immunology, and infectious diseases. Directly comparable to MSD Romania across hospital specialty channels and government health authority engagement.

TypeDirect peer
Description

Romanian subsidiary of Eli Lilly and Company with a strong diabetes and oncology footprint. Overlaps directly with MSD Romania's diabetes and oncology franchises and competes for the same specialist prescriber base and reimbursement decisions.

TypeDirect peer
Description

Romanian subsidiary of Bayer AG spanning pharmaceuticals and consumer health, including cardiology and women's health. Comparable to MSD Romania as a multinational pharma subsidiary with hospital and pharmacy channel presence in Romania.

7Pfizer Romania
TypeDirect peer
Description

Romanian subsidiary of Pfizer Inc., operating across vaccines, oncology, infectious diseases, and internal medicine. Closely comparable to MSD Romania in scale, therapeutic breadth, and reliance on government vaccination tenders and hospital procurement in Romania.

TypeDirect peer
Description

Romanian subsidiary of AstraZeneca PLC covering oncology, cardiovascular/metabolic, and respiratory. Overlaps with MSD Romania's oncology and cardio-metabolic focus and competes for the same hospital and government channels.

TypeDirect peer
Description

Romanian subsidiary of AbbVie Inc., with strong immunology and oncology overlap. Comparable to MSD Romania as a specialty pharma subsidiary competing for hospital reimbursement and prescriber share in Romania.

TypeDirect peer
Description

Romanian subsidiary of GSK plc with significant overlap in vaccines (HPV, pediatric, travel) and infectious disease. Directly comparable to MSD Romania in national vaccination program participation and respiratory/specialty pharma.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

MSD Romania

Biopharmaceuticalsmsd.ro

MSD Romania (Merck Sharp & Dohme Romania SRL) is the Romanian and Moldovan affiliate of Merck & Co., commercializing innovative prescription medicines in oncology, vaccines, infectious diseases, and cardiovascular/metabolic diseases through NHIH reimbursement, hospital channels, and physician field forces.

What MSD Romania does

MSD Romania operates as Merck Sharp & Dohme Romania SRL, a wholly-owned subsidiary of Merck & Co., Inc. (NYSE: MRK) and the local affiliate of the global pharmaceutical company known as MSD outside North America. The Romanian entity commercializes the parent company's innovative prescription medicines across four primary therapeutic areas: oncology, vaccines, infectious diseases, and cardiovascular/metabolic diseases. It serves the Romanian market and, following a regional restructuring into the MEDEBA cluster, extends coverage to the Republic of Moldova. The subsidiary employs approximately 136 staff focused on medical affairs, market access, regulatory, and commercial field operations supporting physicians, hospitals, and the national health insurance system.

The company's core product portfolio mirrors the parent company's global launches in oncology and vaccines, with established positions in immuno-oncology (Keytruda-class therapies inherited from group development), HPV and other vaccines, HIV antiretrovirals (expanded via the 2021 Gilead partnership), and chronic disease treatments. Its business model is a classic multinational pharma go-to-market: it sells reimbursed prescription medicines primarily through the National Health Insurance House (CNAS/NHIH) framework, with secondary channels through hospital tenders, retail pharmacies, and physician-detailing field forces. Revenue mechanics depend on obtaining and maintaining reimbursement listings, winning hospital tenders, and driving physician adoption — a model exposed to public-procurement cycles and reference-pricing pressure. No local manufacturing is indicated; products are supplied through the group's regional and global supply chain.

Beyond commercial operations, MSD Romania has built a public-health and CSR footprint, including the MSD for Mothers partnership with World Vision Romania (2016) targeting maternal mortality, a $50,000 cancer health-literacy research grant with Babeș-Bolyai University (2023), and participation in the AMR Industry Alliance (2016) and AMR Action Fund (2020). In 2023 the company achieved Best Place to Work certification, indicating investment in employer brand in a competitive CEE pharma talent market. Following the May 2026 leadership transition — Conor Dempsey replacing Marcelo Pascual Morales as Managing Director — the affiliate is positioned for continued emphasis on oncology, vaccines, and cardio-metabolic franchises within Romania and Moldova.

MSD Romania firmographics

Firmographics
Name
MSD Romania
Legal name
Merck Sharp & Dohme Romania SRL
Website
https://msd.ro
Company type
Private
Operating status
Operating
Headcount range
101–250 employees
Short description
MSD Romania (Merck Sharp & Dohme Romania SRL) is the Romanian and Moldovan affiliate of Merck & Co., commercializing innovative prescription medicines in oncology, vaccines, infectious diseases, and cardiovascular/metabolic diseases through NHIH reimbursement, hospital channels, and physician field forces.
Ownership category
akta.pro rank

MSD Romania industry classification

Industry
Product category
Biopharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro industry
PRIMARYHLAIAEAN
Vaccine Procurement, Tendering & Immunization Supply Programs
SECONDARYAFAEANAK
Veterinary Pharmacy, Vaccine & Biologics Services

Keywords

  • Prescription pharmaceuticals
  • Vaccine development
  • Oncology therapies
  • Infectious disease treatments
  • Animal health products

Where MSD Romania is headquartered

Location

Headquarters

HQ city
București
HQ country
Romania
HQ region
Europe

Offices1 record

Markets served

MSD Romania business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Marketing or Sales, Supply Chain, Operations

Revenue model

  1. Prescription Medicines: MSD generates revenue through prescription pharmaceutical products including oncology treatments, cardiovascular medications, diabetes treatments, and other therapeutic areas. Revenue is generated through healthcare provider prescriptions and hospital procurement.
  2. Vaccines: Revenue from vaccine products including HPV vaccine, pediatric vaccines (rotavirus, measles-mumps-rubella), and adult vaccines. Distributed approximately 203 million doses globally in 2022.
  3. Hospital Acute Care Products: Products for hospital settings including antibiotics and antifungics for inpatient care, contributing to the Hospital Acute Care division.
  4. Animal Health Products: MSD Animal Health division provides veterinary products and vaccines, operating as a separate business unit with global presence.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractStandard pharmaceutical pricing through prescription and hospital procurement

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

MSD Romania product offering

Product offering

Core offering

MSD Romania is the Romanian subsidiary of Merck & Co., Inc., operating as a biopharmaceutical company that develops, manufactures, and distributes prescription medicines, vaccines, and animal health products across therapeutic areas including oncology, vaccines, infectious diseases (HIV, hepatitis C, antibiotics, antifungals), cardiovascular and metabolic diseases (including type 2 diabetes), and hospital acute care. The company sells primarily to hospitals, healthcare providers, government health programs, and pharmacies, with a separate MSD Animal Health division serving veterinarians and livestock producers.

Product overview

MSD Romania operates as the Romanian subsidiary of Merck Sharp & Dohme (MSD), a global biopharmaceutical company known as Merck & Co. in the US and Canada. The company offers a comprehensive portfolio of prescription medicines and vaccines across multiple therapeutic areas including oncology (with treatments for 30+ cancer types), vaccines (protecting against 20+ diseases with 203M doses distributed globally in 2022), infectious diseases (HIV with 35 years of research, Ebola, antibiotics since 1942), cardiovascular and metabolic diseases (including diabetes), and hospital care products. MSD also operates an Animal Health division. The company's research and development process encompasses drug discovery, pre-clinical development, clinical development, and real-world evidence generation through its CORE center. With over 130 years of pharmaceutical innovation, MSD Romania focuses on bringing innovative medicines to the Romanian market through its network of operations in Romania and the Republic of Moldova.

Differentiator

Problem solved

Functional benefit

Brands

  • MSD for Mothers: A 10-year, $500 million initiative that applies MSD's scientific expertise and business resources to reduce maternal mortality globally. In Romania, MSD for Mothers partnered with World Vision Romania in 2016.
  • MSD Animal Health
  • MSD Wellcome Trust Hilleman Laboratories

Products and services

  • Oncology Therapies

Quantifiable outcome

  • 400,000+ oncology patients treated in the last 5 years
  • +4 more outcomes

Companies that use MSD Romania

Customer profile

Segments3 records

Ideal customer profiles3 records

MSD Romania technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

MSD Romania partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core and minor.

  • Universitatea Babeș-Bolyai (UBB)coreStrategic or Co-development Partner · 27 March 2023Departamentul de Sănătate Publică al Universității Babeș-Bolyai and MSD România launched a health policy research project analyzing how improving cancer literacy can reduce inequities in cancer treatment. The project, funded with $50,000 through MSD's Global Cancer Health Policy Grants Program, will develop policy recommendations to improve access to information and medical services for oncology patients. Implemented over 12 months using evidence-based and personalized approaches in the bio-psycho-social model framework.
  • Onco-alliance (Slovakia)coreStrategic or Co-development Partner · 1 November 2022Strategic oncology alliance supporting implementation of European-funded projects worth over 8 million euros for oncology infrastructure and digitization. Projects focused on colon cancer, breast cancer, and lung cancer improvement initiatives.
  • Gilead SciencesminorStrategic or Co-development Partner · 1 January 2021MSD entered into an agreement with Gilead to collaborate within the global HIV community in the fight against HIV, combining capabilities to address this ongoing public health challenge.
  • Antimicrobial Resistance (AMR) Action FundminorStrategic or Co-development Partner · 1 January 2020MSD, together with over 20 leading biopharmaceutical companies, launched the AMR Action Fund to make 2-4 new antibiotics available to patients by the end of the decade. This initiative addresses the critical need for new antimicrobial treatments in the face of growing resistance.
  • World Vision RomâniacoreStrategic or Co-development Partner · 1 January 2016MSD Romania and World Vision Romania Foundation launched a comprehensive program to reduce maternal mortality in Romania as part of the global MSD for Mothers initiative. The program develops an integrated and innovative model of family planning, reproductive health, and pregnant women assistance services in disadvantaged areas of the country. The global MSD for Mothers initiative is a 10-year, $500 million commitment to reducing maternal mortality globally.
  • AMR Industry AllianceminorStrategic or Co-development Partner · 1 January 2016MSD joined the AMR Industry Alliance, a network of over 100 pharmaceutical industry partners working to provide sustainable solutions to help reduce antimicrobial resistance. The alliance represents one of the largest private sector coalitions addressing AMR globally.
  • One Health Global Leaders Group on Antimicrobial ResistanceminorStrategic or Co-development PartnerMSD participates as an industry representative in the One Health Global Leaders Group on Antimicrobial Resistance, advocating for a One Health approach to ensure antibiotics remain an important tool for improving and maintaining human and animal health.

Scale indicators7 records

Recent moves7 records

Expansion highlights5 records

MSD Romania competitors and assessment

Company assessment

Direct peers

  • Sanofi Romania: Romanian subsidiary of Sanofi S.A., with strong overlap in vaccines, diabetes, and rare diseases. Comparable to MSD Romania in pediatric and adult vaccine portfolios and in diabetes/cardio-metabolic therapeutic areas.
  • Roche Romania: Romanian subsidiary of Roche Group with a strong oncology and diagnostics overlap. Directly comparable to MSD Romania in oncology positioning, hospital channel focus, and participation in national cancer control planning.
  • Novartis Romania: Romanian subsidiary of Novartis AG covering oncology, cardiovascular, and immunology portfolios. Comparable to MSD Romania as a top-tier multinational pharma subsidiary competing for hospital formularies and reimbursement in Romania.
  • Johnson & Johnson (Janssen) Romania: Romanian pharmaceutical operations of Johnson & Johnson covering oncology, immunology, and infectious diseases. Directly comparable to MSD Romania across hospital specialty channels and government health authority engagement.
  • Eli Lilly Romania: Romanian subsidiary of Eli Lilly and Company with a strong diabetes and oncology footprint. Overlaps directly with MSD Romania's diabetes and oncology franchises and competes for the same specialist prescriber base and reimbursement decisions.
  • Bayer Romania: Romanian subsidiary of Bayer AG spanning pharmaceuticals and consumer health, including cardiology and women's health. Comparable to MSD Romania as a multinational pharma subsidiary with hospital and pharmacy channel presence in Romania.
  • Pfizer Romania: Romanian subsidiary of Pfizer Inc., operating across vaccines, oncology, infectious diseases, and internal medicine. Closely comparable to MSD Romania in scale, therapeutic breadth, and reliance on government vaccination tenders and hospital procurement in Romania.
  • AstraZeneca Romania: Romanian subsidiary of AstraZeneca PLC covering oncology, cardiovascular/metabolic, and respiratory. Overlaps with MSD Romania's oncology and cardio-metabolic focus and competes for the same hospital and government channels.
  • AbbVie Romania: Romanian subsidiary of AbbVie Inc., with strong immunology and oncology overlap. Comparable to MSD Romania as a specialty pharma subsidiary competing for hospital reimbursement and prescriber share in Romania.
  • GSK Romania: Romanian subsidiary of GSK plc with significant overlap in vaccines (HPV, pediatric, travel) and infectious disease. Directly comparable to MSD Romania in national vaccination program participation and respiratory/specialty pharma.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

MSD Romania social profiles

Digital presence

MSD Romania financial estimates

Financial estimate

Revenue estimate

Valuation estimate

MSD Romania leadership team

Management profile

Number of profiles

Profiles5 records

MSD Romania funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

MSD Romania M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MSD Romania

What does MSD Romania do?

MSD Romania is the Romanian subsidiary of Merck & Co., Inc., operating as a biopharmaceutical company that develops, manufactures, and distributes prescription medicines, vaccines, and animal health products across therapeutic areas including oncology, vaccines, infectious diseases (HIV, hepatitis C, antibiotics, antifungals), cardiovascular and metabolic diseases (including type 2 diabetes), and hospital acute care. The company sells primarily to hospitals, healthcare providers, government health programs, and pharmacies, with a separate MSD Animal Health division serving veterinarians and livestock producers.

Is MSD Romania a public or private company?

MSD Romania is a private company. It is classified as corporate owned and is currently operating.

When was MSD Romania founded?

MSD Romania was founded in -1. It employs 101 to 250 people.

Where is MSD Romania based?

MSD Romania is headquartered in București, Romania, in the Europe region.

How does MSD Romania make money?

Four revenue lines are on record. Prescription Medicines are the primary driver. The others are vaccines, hospital Acute Care Products and animal Health Products.

Who are MSD Romania's main competitors?

Direct peers on record are Sanofi Romania, Roche Romania, Novartis Romania, Johnson & Johnson (Janssen) Romania, Eli Lilly Romania, Bayer Romania, Pfizer Romania, AstraZeneca Romania, AbbVie Romania and GSK Romania.

Does MSD Romania have an API?

No public API is recorded for MSD Romania.

What industry is MSD Romania in?

MSD Romania's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAIAEAN, Vaccine Procurement, Tendering & Immunization Supply Programs, with a secondary code of AFAEANAK, Veterinary Pharmacy, Vaccine & Biologics Services. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales